Anemia is common in the patients with chronic kidney disease (CKD). It usually appears in stage 4, but it is not rare even in stage 3 of the CKD. It is mandatory to evaluate the patients with signs of CKD on the presence of renal anemia. Early anemia treatment, both in the stages 3 and 4, is associated with less cardiovascular events and better quality of life of this patient population. Treatment of renal anemia is possible with all erythropoiesis stimulating agents (ESAs). Newer formulations may cause less hemoglobin variations and prolonged treatment interval. There are some evidences about beneficial treatment of renal anemia causing slower progression of CKD, but we need further controlled, randomized clinical trials to prove these observations.